AstraZeneca (AZN) Given a GBX 4,840 Price Target at HSBC

AstraZeneca (LON:AZN) received a GBX 4,840 ($61.74) price objective from HSBC in a research note issued on Wednesday. The brokerage currently has a “sell” rating on the biopharmaceutical company’s stock. HSBC’s price objective suggests a potential downside of 18.46% from the stock’s previous close.

A number of other analysts have also weighed in on the stock. Berenberg Bank restated a “buy” rating and issued a GBX 6,200 ($79.09) target price on shares of AstraZeneca in a research report on Friday, June 8th. Deutsche Bank restated a “buy” rating and issued a GBX 6,000 ($76.54) target price (up previously from GBX 5,700 ($72.71)) on shares of AstraZeneca in a research report on Friday, July 13th. Goldman Sachs Group set a GBX 3,750 ($47.84) target price on shares of AstraZeneca and gave the company a “sell” rating in a research report on Wednesday, April 18th. Shore Capital restated a “hold” rating and issued a GBX 4,965 ($63.34) target price on shares of AstraZeneca in a research report on Thursday, April 19th. Finally, JPMorgan Chase & Co. restated an “overweight” rating and issued a GBX 5,500 ($70.16) target price on shares of AstraZeneca in a research report on Tuesday, April 24th. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of GBX 5,605.09 ($71.50).

Shares of AstraZeneca stock opened at GBX 5,936 ($75.72) on Wednesday. AstraZeneca has a fifty-two week low of GBX 4,260 ($54.34) and a fifty-two week high of GBX 5,520 ($70.42).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What does relative strength index mean?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply